OBJECTIVES: To investigate the effectiveness of low dose secondary/tertiary prophylaxis in severe Hemophilia A children and determine improvements in their daily life. METHODS: Thirty Hemophilia A children (≤ 12 y) with factor VIII <2% and less than two joint bleeds without inhibitors, were given prophylaxis with recombinant Fc fusion long acting factor VIII (ELOCTATE) at 10 IU.kg-1 twice weekly for 1 y. Earlier, patients received on-demand FVIII for a minimum of six months. Outcome was measured in terms of annual bleeding rate, Hemophilia Joint Health Score (HJHS) and child activity/participation was measured in terms of school absenteeism, School Activity Participation Score and Daily Activity Score according to Beijing Children Hospital assessment scale. RESULTS: A total of 30 children were included in the study. There was reduction in annual joint bleeds by 85.76% (14.5 to 2.2) and school absenteeism (days/month) by 86% (17.38 to 2.42) before and after prophylaxis respectively. Majority (43%) showed moderate improvement in daily activity score. Mean HJHS score was 8.3. There was mild improvement in School Activity Participation Score in 57%. Mean annual hospitalization rate reduced from 8.7 to 1.1 with improvement in joint scores. Mean annual factor consumption decreased from 1944.2 IU.kg-1 to 1560.3 IU.kg-1. CONCLUSIONS: With low dose secondary/tertiary prophylaxis, there is significant reduction in the annual joint bleed rate with improvement in joint health and child activity. As factor consumption is reduced, this has a positive effect on cost benefit; and is a very feasible option in developing countries.
OBJECTIVES: To investigate the effectiveness of low dose secondary/tertiary prophylaxis in severe Hemophilia Achildren and determine improvements in their daily life. METHODS: Thirty Hemophilia Achildren (≤ 12 y) with factor VIII <2% and less than two joint bleeds without inhibitors, were given prophylaxis with recombinant Fc fusion long acting factor VIII (ELOCTATE) at 10 IU.kg-1 twice weekly for 1 y. Earlier, patients received on-demand FVIII for a minimum of six months. Outcome was measured in terms of annual bleeding rate, Hemophilia Joint Health Score (HJHS) and child activity/participation was measured in terms of school absenteeism, School Activity Participation Score and Daily Activity Score according to Beijing Children Hospital assessment scale. RESULTS: A total of 30 children were included in the study. There was reduction in annual joint bleeds by 85.76% (14.5 to 2.2) and school absenteeism (days/month) by 86% (17.38 to 2.42) before and after prophylaxis respectively. Majority (43%) showed moderate improvement in daily activity score. Mean HJHS score was 8.3. There was mild improvement in School Activity Participation Score in 57%. Mean annual hospitalization rate reduced from 8.7 to 1.1 with improvement in joint scores. Mean annual factor consumption decreased from 1944.2 IU.kg-1 to 1560.3 IU.kg-1. CONCLUSIONS: With low dose secondary/tertiary prophylaxis, there is significant reduction in the annual joint bleed rate with improvement in joint health and child activity. As factor consumption is reduced, this has a positive effect on cost benefit; and is a very feasible option in developing countries.
Entities:
Keywords:
Children up to 12 y; Developing countries; Hemophilia A; Low dose; Secondary/Tertiary prophylaxis
Authors: S P Verma; T K Dutta; S Mahadevan; P Nalini; D Basu; N Biswal; A Ramesh; D Charles; K V Vinod; K T Harichandra Kumar Journal: Haemophilia Date: 2016-03-14 Impact factor: 4.287
Authors: P Hilliard; N Zourikian; V Blanchette; A Chan; B Elliott; S J Israels; J Nilson; M-C Poon; N Laferriere; C Van Neste; C Jarock; J Wu; M McLimont; B Feldman Journal: J Thromb Haemost Date: 2013-03 Impact factor: 5.824
Authors: Johnny Mahlangu; Jerry S Powell; Margaret V Ragni; Pratima Chowdary; Neil C Josephson; Ingrid Pabinger; Hideji Hanabusa; Naresh Gupta; Roshni Kulkarni; Patrick Fogarty; David Perry; Amy Shapiro; K John Pasi; Shashikant Apte; Ivan Nestorov; Haiyan Jiang; Shuanglian Li; Srividya Neelakantan; Lynda M Cristiano; Jaya Goyal; Jurg M Sommer; Jennifer A Dumont; Nigel Dodd; Karen Nugent; Gloria Vigliani; Alvin Luk; Aoife Brennan; Glenn F Pierce Journal: Blood Date: 2013-11-13 Impact factor: 22.113
Authors: J M Sommer; N Moore; B McGuffie-Valentine; S Bardan; Y Buyue; G D Kamphaus; B A Konkle; G F Pierce Journal: Haemophilia Date: 2013-11-22 Impact factor: 4.287
Authors: Vyas K Rathaur; N K V Vigneshwar; Ayesha Imran; Monika Pathania; Sonam Agrawal; Swathi Chacham; Prashant K Verma; Nowneet K Bhat Journal: J Family Med Prim Care Date: 2021-04-08